Compositions and methods for inhibition of e. coli hemolysin during urinary tract infection

Abstract

Compositions and methods for treating urinary tract infection (UTI) and/or sepsis in a subject in need thereof are provided. Methods include administering to the subject a composition comprising an alpha-hemolysin (HlyA) inhibiting agent. In some embodiments, the HlyA inhibiting agent includes a soluble low-density lipoprotein receptor (LDLR)-Fc fusion protein as described herein, a clathrin-mediated endocytosis (CME) inhibitor, and/or an anti-LDLR antibody. In some embodiments, the soluble LDLR-Fc fusion protein includes an Fc domain and at least one LDLR type A domain. In some embodiments, the UTI and/or sepsis is caused by E. coli.

Dependencies are inferred from the claim text.